Session 8-1: EZ Biosciences, Inc.

M. D. Anderson Cancer Center
Date: April 2008
Duration: 0 / 04:42

Raymond Mouzannar, Ph.D., Scientific Advisor, EZ Biosciences, Inc..

Hello, everyone. I am Raymen Mouzannar. I am the scientific advisor to EZ Biosciences, Inc. I am here to tell you about the company and hopefully you convince you to invest in our mission and our business school.

EZ Bioscience's mission is to innovate and develop platform to causes to make biological research easier. By automating lengthy biological experiments and procedures. And there are many of those.

One of them is the immunoblot. It's an acid that detects proteins. Proteins we know; they are the major targets for drug discovery. So, no wonder they're used by most biological labs. However, there's a drawback to this assay. It's time consuming. Needs hours of repeated labor and monitoring. And shows inconsistent results and everybody complains about it.

Our market is global. We are assessing this currently. It comprises biological research labs. Seventy percent of those are represented by institutions and the rest by government agencies and life science industries. However, we're currently targeting the largest medical center in the world, the Texas Medial Center. That comprises almost 350 labs, and to give you a snapshot, this center has consumed one billion dollars on basic research last year.

So, our leading product is the EZ-Blot. This product will automate the hours long process traditionally takes into one set-up of minutes. What is shown here on the right is a parallel comparison of the traditional blot to the EZ-Blot. Basically what I'm showing you here is a reduction of repetitive steps that would take hours to days. Into a simple minute set-up from start to finish, and you have a complete assay, reproducible, customizable, without any errors. Again, the advantages of this machine is that it reduces human labor from days to minutes, eliminates monitoring and therefore human errors. It's customizable. Most importantly, scientifically reproducible. And has a possible use for other applications.

How do we stand up? There are no currently competitive players that directly have an impact on the immunoblot; however, there are other companies that do have other protein detection assays. These are costly. They are not available in every lab. And most importantly still have a reproducibility issue. We do have an intellectual property that is provisional currently. We are assessing the use of this machine to other procedures and willing to present a... to submit a full application as soon as we start up.

So, we are at the developmental stage. We are building a prototype. We found at least 80 local manufacturers that are competing to build our prototype. So we're waiting for the current bidder, the winner of the bid to move forward. So we are seeking a half million dollar as a seed to form this company, to protect our right and to develop our prototype, the EZ-Blot. Along with other pipelines that we have in development. As a ball park figure, we estimate that we will generate a 150% revenue and a return of investment within two years. Of course, this cannot be done without prominent members from within the scientific community. The two founders that have over 10 years of experience in industry and academia will push this company into success. So ladies and gentlemen, I present to you EZ Biosciences.

Can take any questions from now. Thank you.

[Applause]